Contineum Therapeutics (CTNM) Competitors $7.07 -0.38 (-5.10%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$7.10 +0.02 (+0.35%) As of 03/28/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTNM vs. CDMO, QURE, CMRX, PRAX, BCAX, LENZ, ABCL, CRON, PRTA, and AVBPShould you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Avid Bioservices (CDMO), uniQure (QURE), Chimerix (CMRX), Praxis Precision Medicines (PRAX), Bicara Therapeutics (BCAX), LENZ Therapeutics (LENZ), AbCellera Biologics (ABCL), Cronos Group (CRON), Prothena (PRTA), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry. Contineum Therapeutics vs. Avid Bioservices uniQure Chimerix Praxis Precision Medicines Bicara Therapeutics LENZ Therapeutics AbCellera Biologics Cronos Group Prothena ArriVent BioPharma Contineum Therapeutics (NASDAQ:CTNM) and Avid Bioservices (NASDAQ:CDMO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, community ranking, valuation and risk. Does the media prefer CTNM or CDMO? In the previous week, Contineum Therapeutics had 1 more articles in the media than Avid Bioservices. MarketBeat recorded 1 mentions for Contineum Therapeutics and 0 mentions for Avid Bioservices. Contineum Therapeutics' average media sentiment score of 1.89 beat Avid Bioservices' score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Contineum Therapeutics Very Positive Avid Bioservices Neutral Which has stronger earnings & valuation, CTNM or CDMO? Contineum Therapeutics has higher earnings, but lower revenue than Avid Bioservices. Avid Bioservices is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContineum Therapeutics$50M3.66$22.72M-$4.90-1.44Avid Bioservices$139.91M5.71-$140.75M-$2.39-5.23 Is CTNM or CDMO more profitable? Contineum Therapeutics has a net margin of 0.00% compared to Avid Bioservices' net margin of -101.07%. Avid Bioservices' return on equity of -33.18% beat Contineum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Contineum TherapeuticsN/A -49.92% -20.52% Avid Bioservices -101.07%-33.18%-8.45% Do analysts rate CTNM or CDMO? Contineum Therapeutics presently has a consensus target price of $24.80, suggesting a potential upside of 250.78%. Avid Bioservices has a consensus target price of $12.25, suggesting a potential downside of 1.96%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Contineum Therapeutics is more favorable than Avid Bioservices.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Avid Bioservices 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community prefer CTNM or CDMO? Avid Bioservices received 359 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 65.95% of users gave Avid Bioservices an outperform vote. CompanyUnderperformOutperformContineum TherapeuticsOutperform Votes11100.00% Underperform VotesNo VotesAvid BioservicesOutperform Votes37065.95% Underperform Votes19134.05% Do institutionals & insiders hold more shares of CTNM or CDMO? 97.2% of Avid Bioservices shares are held by institutional investors. 3.1% of Avid Bioservices shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryContineum Therapeutics beats Avid Bioservices on 10 of the 18 factors compared between the two stocks. Remove Ads Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTNM vs. The Competition Export to ExcelMetricContineum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$182.92M$6.91B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.01%P/E Ratio-1.447.1723.3318.67Price / Sales3.66220.47388.4691.01Price / Cash6.3565.6738.1634.64Price / Book-1.906.396.894.23Net Income$22.72M$142.12M$3.20B$247.15M7 Day Performance-1.39%-5.06%-2.98%-2.17%1 Month Performance0.43%-7.49%1.63%-5.68%1 Year PerformanceN/A-10.91%9.44%-0.74% Contineum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTNMContineum Therapeutics2.1579 of 5 stars$7.07-5.1%$24.80+250.8%N/A$182.92M$50M-1.4431Positive NewsCDMOAvid Bioservices0.9925 of 5 stars$12.50+0.1%$12.25-2.0%+86.5%$799.18M$139.91M-5.23320High Trading VolumeQUREuniQure2.6718 of 5 stars$14.77+7.8%$38.89+163.3%+139.8%$798.72M$27.12M-2.98500CMRXChimerix3.4997 of 5 stars$8.50flat$8.53+0.4%+701.9%$764.46M$159,000.00-9.0490Earnings ReportShort Interest ↓PRAXPraxis Precision Medicines2.5063 of 5 stars$37.71+1.6%$123.80+228.3%-36.6%$760.35M$8.55M-3.66110BCAXBicara TherapeuticsN/A$13.80+4.2%$36.50+164.5%N/A$750.94MN/A0.0032Earnings ReportAnalyst ForecastNews CoverageLENZLENZ Therapeutics1.7393 of 5 stars$26.66+0.6%$41.67+56.3%+14.8%$733.18MN/A-5.59110ABCLAbCellera Biologics2.4374 of 5 stars$2.59+6.1%$7.00+170.3%-49.0%$727.09M$28.83M-4.25500Positive NewsCRONCronos Group1.8875 of 5 stars$1.88+5.0%$3.00+59.6%-31.4%$719.16M$117.62M-14.46450PRTAProthena3.2972 of 5 stars$13.34+2.9%$55.00+312.3%-47.0%$718.05M$135.16M-5.80130Analyst RevisionNews CoveragePositive NewsAVBPArriVent BioPharma1.4139 of 5 stars$20.21+3.5%$39.00+93.0%+6.1%$687.46MN/A-7.8640 Remove Ads Related Companies and Tools Related Companies CDMO Competitors QURE Competitors CMRX Competitors PRAX Competitors BCAX Competitors LENZ Competitors ABCL Competitors CRON Competitors PRTA Competitors AVBP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTNM) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
